Phreesia, Inc. (0A23.L)
USD 25.52
(2.82%)
USD 25.52
(2.82%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 371.08 Million USD | 0.07% |
| 2023 | 370.05 Million USD | -25.16% |
| 2022 | 494.47 Million USD | 51.37% |
| 2021 | 326.66 Million USD | 105.76% |
| 2020 | 158.75 Million USD | 167.89% |
| 2019 | 59.26 Million USD | 3.72% |
| 2018 | 57.13 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 371.08 Million USD | -0.95% |
| 2024 FY | 371.08 Million USD | 0.28% |
| 2024 Q1 | 353.85 Million USD | -4.38% |
| 2024 Q2 | 340.44 Million USD | -3.79% |
| 2024 Q3 | 374.64 Million USD | 10.05% |
| 2023 Q1 | 459.09 Million USD | -7.16% |
| 2023 Q4 | 370.05 Million USD | -6.86% |
| 2023 FY | 370.05 Million USD | -25.16% |
| 2023 Q3 | 397.29 Million USD | -6.74% |
| 2023 Q2 | 425.98 Million USD | -7.21% |
| 2022 Q2 | 551.22 Million USD | -1.78% |
| 2022 Q4 | 494.47 Million USD | -6.55% |
| 2022 Q3 | 529.12 Million USD | -4.01% |
| 2022 Q1 | 561.2 Million USD | 71.8% |
| 2022 FY | 494.47 Million USD | 51.37% |
| 2021 FY | 326.66 Million USD | 105.76% |
| 2021 Q1 | 161.3 Million USD | 1.6% |
| 2021 Q2 | 160.28 Million USD | -0.63% |
| 2021 Q3 | 338.05 Million USD | 110.9% |
| 2021 Q4 | 326.66 Million USD | -3.37% |
| 2020 Q1 | 68.1 Million USD | 14.93% |
| 2020 FY | 158.75 Million USD | 167.89% |
| 2020 Q2 | 162.98 Million USD | 139.31% |
| 2020 Q4 | 158.75 Million USD | 1.83% |
| 2020 Q3 | 155.9 Million USD | -4.34% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | 59.26 Million USD | 0.0% |
| 2019 FY | 59.26 Million USD | 3.72% |
| 2018 FY | 57.13 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Accuray Incorporated | 468.62 Million USD | 20.814% |
| Align Technology, Inc. | 6.08 Billion USD | 93.901% |
| Elevance Health Inc. | 108.92 Billion USD | 99.659% |
| AxoGen, Inc. | 196.82 Million USD | -88.534% |
| Boston Scientific Corporation | 35.13 Billion USD | 98.944% |
| CVS Health Corporation | 249.72 Billion USD | 99.851% |
| Cardinal Health, Inc. | 45.12 Billion USD | 99.178% |
| Centene Corporation | 84.64 Billion USD | 99.562% |
| DaVita Inc. | 17.61 Billion USD | 97.894% |
| HCA Healthcare, Inc. | 56.21 Billion USD | 99.34% |
| Hologic, Inc. | 9.15 Billion USD | 95.947% |
| Humana Inc. | 47.06 Billion USD | 99.212% |
| IDEXX Laboratories, Inc. | 3.25 Billion USD | 88.617% |
| Laboratory Corporation of America Holdings | 16.72 Billion USD | 97.781% |
| Masimo Corporation | 3.04 Billion USD | 87.799% |
| McKesson Corporation | 67.44 Billion USD | 99.45% |
| Patterson Companies, Inc. | 2.96 Billion USD | 87.502% |
| Quest Diagnostics Incorporated | 14.02 Billion USD | 97.354% |
| ResMed Inc. | 6.87 Billion USD | 94.6% |
| Henry Schein, Inc. | 10.57 Billion USD | 96.49% |
| Teladoc Health, Inc. | 4.39 Billion USD | 91.552% |
| Universal Health Services, Inc. | 14.35 Billion USD | 97.415% |
| Veeva Systems Inc. | 5.91 Billion USD | 93.722% |
| Baxter International Inc. | 28.27 Billion USD | 98.688% |
| Becton, Dickinson and Company | 52.78 Billion USD | 99.297% |
| Intuitive Surgical, Inc. | 15.44 Billion USD | 97.597% |
| Danaher Corporation | 84.48 Billion USD | 99.561% |
| Stryker Corporation | 39.91 Billion USD | 99.07% |
| Medtronic plc | 89.98 Billion USD | 99.588% |